Introduction/Background Personalised care and targeted therapy approaches in aOC have evolved during the last decade with introduction of bevacizumab to platinum-doublet chemotherapy being one of these early advances during this period. This observational, retrospective database study builds on previously published real-world evidence describing patient characteristics and outcomes in newly diagnosed aOC patients treated with systemic therapy with/without bevacizumab.

Methodology Newly diagnosed aOC patients (stage III/IV) were selected from the National Cancer Registration Dataset 01/08/2014 through 31/12/2018. This work includes patient data collated by the National Disease Registration Service. Patients aged ≥18 years at diagnosis, with no other cancers diagnosed in the five years prior to aOC, treated with systemic anti-cancer therapy (SACT) were included. Follow-up ended 31/12/2019. An algorithm defined probable therapy line occurring after aOC diagnosis. Time to next treatment (TTNT): days from start of first-line therapy to start of second-line therapy. Characteristics, treatment patterns and outcomes were described overall and by a sub-cohort receiving bevacizumab in first-line.

Results In the 8717 patients, median age at first-line therapy start was 68.8 (Inter-Quartile-Range (IQR):59.8–75.7) years, 2968 (34%) were diagnosed at stage IV and 1717 (20%) had recorded performance status (PS) 2–3 during first-line. Total, 5505 (63%) received surgery; 2556 (29%) had surgery before first-line therapy. Median TTNT was 331 (IQR:194–488) days in patients observed receiving second-line (n=4193 (48%)). Total 1833 (21%) received bevacizumab in first-line. This sub-cohort had median age 64.8 (IQR:56.4–71.3) years; 921 (50%) were diagnosed at stage IV; 210 (11%) had recorded PS 2–3 during first-line. Median bevacizumab cycles was 11 (IQR:6–16). Surgery occurred in 1291 (70%) patients, with 420 (23%) receiving surgery before first-line. Median TTNT was 426.5 (IQR:309.5–602) days in patients observed receiving second-line (n=972 (53%)).

Conclusion These observations add to the collective body of evidence regarding the changing treatment landscape in aOC.